LIPO vs. TPST, CGTX, PASG, CYTH, LEXX, DRRX, KALA, LGVN, CALC, and GRCE
Should you be buying Lipella Pharmaceuticals stock or one of its competitors? The main competitors of Lipella Pharmaceuticals include Tempest Therapeutics (TPST), Cognition Therapeutics (CGTX), Passage Bio (PASG), Cyclo Therapeutics (CYTH), Lexaria Bioscience (LEXX), DURECT (DRRX), KALA BIO (KALA), Longeveron (LGVN), CalciMedica (CALC), and Grace Therapeutics (GRCE). These companies are all part of the "pharmaceutical products" industry.
Lipella Pharmaceuticals vs.
Lipella Pharmaceuticals (NASDAQ:LIPO) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, community ranking, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.
Lipella Pharmaceuticals has higher revenue and earnings than Tempest Therapeutics. Lipella Pharmaceuticals is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.
Tempest Therapeutics has a net margin of 0.00% compared to Lipella Pharmaceuticals' net margin of -882.82%. Tempest Therapeutics' return on equity of -187.44% beat Lipella Pharmaceuticals' return on equity.
Tempest Therapeutics has a consensus price target of $30.00, indicating a potential upside of 312.09%. Given Tempest Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tempest Therapeutics is more favorable than Lipella Pharmaceuticals.
Tempest Therapeutics received 101 more outperform votes than Lipella Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Lipella Pharmaceuticals an outperform vote while only 65.38% of users gave Tempest Therapeutics an outperform vote.
74.3% of Lipella Pharmaceuticals shares are owned by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are owned by institutional investors. 32.1% of Lipella Pharmaceuticals shares are owned by insiders. Comparatively, 4.7% of Tempest Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, Lipella Pharmaceuticals and Lipella Pharmaceuticals both had 1 articles in the media. Lipella Pharmaceuticals' average media sentiment score of 1.00 beat Tempest Therapeutics' score of 0.55 indicating that Lipella Pharmaceuticals is being referred to more favorably in the media.
Lipella Pharmaceuticals has a beta of 0.29, indicating that its share price is 71% less volatile than the S&P 500. Comparatively, Tempest Therapeutics has a beta of -2.34, indicating that its share price is 334% less volatile than the S&P 500.
Summary
Lipella Pharmaceuticals beats Tempest Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Lipella Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for LIPO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lipella Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:LIPO) was last updated on 4/20/2025 by MarketBeat.com Staff
Buy LIPO Stock Free LIPO Stock Alerts